Cellular delivery of antisense oligonucleotides.
暂无分享,去创建一个
I Lebedeva | C. Stein | I. Lebedeva | L. Benimetskaya | M. Vilenchik | L Benimetskaya | C A Stein | M Vilenchik
[1] C. Steer,et al. Nucleotide Exchange in Genomic DNA of Rat Hepatocytes Using RNA/DNA Oligonucleotides , 1999, The Journal of Biological Chemistry.
[2] V. Soldatenkov,et al. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer , 1997, Gene Therapy.
[3] P. D. Cook,et al. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. , 1997, Nucleic acids research.
[4] T. Ogihara,et al. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. , 1994, Gene.
[5] T M Allen,et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.
[6] P. Cheng,et al. Lectin conjugate-directed gene transfer to airway epithelial cells. , 1994, Biochemical and biophysical research communications.
[7] A. Gewirtz,et al. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. , 1995, The Journal of clinical investigation.
[8] A. Kabanov,et al. Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. , 1998, Bioconjugate chemistry.
[9] F. Gasparro,et al. CELL MEMBRANE DNA: A NEW TARGET FOR PSORALEN PHOTOADDUCT FORMATION , 1990, Photochemistry and photobiology.
[10] A. Zimmer,et al. Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides. , 1997, Antisense & nucleic acid drug development.
[11] S. Akhtar,et al. Antisense technology: selection and delivery of optimally acting antisense oligonucleotides. , 1998, Journal of drug targeting.
[12] H. Blum,et al. Antisense therapy of hepatitis B virus infection , 1998, Molecular biotechnology.
[13] M. Bassik,et al. DNA vector chemistry: The covalent attachment of signal peptides to plasmid DNA , 1998, Nature Biotechnology.
[14] H. Iishi,et al. In vivo electroporetic transfer of bcl‐2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats , 2000, International journal of cancer.
[15] C. Hélène,et al. Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles. , 1995, European Journal of Biochemistry.
[16] A. Dritschilo,et al. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. , 1992, Nucleic acids research.
[17] J. Loike,et al. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein , 1997, Nature Medicine.
[18] P. Nielsen,et al. Progress in developing PNA as a gene-targeted drug. , 1997, Antisense & nucleic acid drug development.
[19] J. C. Perales,et al. Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[20] R. Morishita,et al. DNA transfer into vascular smooth muscle using fusigenic Sendai virus (HJV)-liposomes , 1997 .
[21] Y. Kaneda,et al. Fusigenic viral liposome for gene therapy in cardiovascular diseases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Madon,et al. Receptor‐mediated delivery of hepatitis B virus DNA and antisense oligodeoxynucleotides to avian liver cells , 1996, Hepatology.
[23] A. Frankel,et al. Endocytosis and targeting of exogenous HIV‐1 Tat protein. , 1991, The EMBO journal.
[24] D. Ma,et al. Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. , 1996, Leukemia research.
[25] B. Sikic,et al. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] J. M. Brown,et al. Fate of cationic liposomes and their complex with oligonucleotide in vivo. , 1996, Biochimica et biophysica acta.
[27] S. Simões,et al. Gene delivery mediated by cationic liposomes: from biophysical aspects to enhancement of transfection. , 1999, Molecular membrane biology.
[28] K. Stecker,et al. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. , 1997, The Journal of pharmacology and experimental therapeutics.
[29] Joseph Zabner,et al. Cellular and Molecular Barriers to Gene Transfer by a Cationic Lipid (*) , 1995, The Journal of Biological Chemistry.
[30] A. Kabanov,et al. Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides , 1999, Nature Biotechnology.
[31] T. Allen,et al. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. , 1995, Biochimica et biophysica acta.
[32] S. Simões,et al. Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells. , 1999, Molecular membrane biology.
[33] D. Ecker,et al. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. , 1992, The Journal of biological chemistry.
[34] P. Couvreur,et al. Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[35] M. Yarmush,et al. Covalent protein-oligonucleotide conjugates for efficient delivery of antisense molecules. , 1997, Bioconjugate chemistry.
[36] W. Wels,et al. Target Cell-specific DNA Transfer Mediated by a Chimeric Multidomain Protein , 1996, The Journal of Biological Chemistry.
[37] J. Fréchet,et al. Functional polymers and dendrimers: reactivity, molecular architecture, and interfacial energy. , 1994, Science.
[38] E. Nabel,et al. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. , 1992, Human gene therapy.
[39] A. Gabizon,et al. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. , 1990, Cancer research.
[40] Kazuo Maruyama,et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.
[41] J. Behr,et al. Liver‐directed gene transfer: a linear polyethylenimine derivative mediates highly efficient DNA delivery to primary hepatocytes in vitro and in vivo , 1998, Journal of viral hepatitis.
[42] W. Pardridge,et al. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[43] D. Corey,et al. Cellular delivery of peptide nucleic acids and inhibition of human telomerase. , 1999, Chemistry & biology.
[44] W. Flanagan,et al. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[45] A. Matsuno,et al. In vitro and in vivo delivery of antisense oligodeoxynucleotides using lipofection: application of antisense technique to growth suppression of experimental glioma. , 2000, Methods in enzymology.
[46] A. Periasamy,et al. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. , 1991, Nucleic acids research.
[47] G. Gregoriadis,et al. Biodistribution, stability, and antiviral efficacy of liposome‐entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection , 1998, Hepatology.
[48] S. Simões,et al. Sterically Stabilized pH-sensitive Liposomes , 1997, The Journal of Biological Chemistry.
[49] M. Monsigny,et al. Cytosolic and nuclear delivery of oligonucleotides mediated by an amphiphilic anionic peptide. , 1997, Antisense & nucleic acid drug development.
[50] B. Calabretta,et al. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. , 1994, British Journal of Cancer.
[51] F. Szoka,et al. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. , 1998, Biochimica et biophysica acta.
[52] P. Ross,et al. Lipoplex size is a major determinant of in vitro lipofection efficiency , 1999, Gene Therapy.
[53] J. C. Martin,et al. Current concepts in antisense drug design. , 1993, Journal of medicinal chemistry.
[54] John W. Park,et al. Cationic Liposomes Coated with Polyethylene Glycol As Carriers for Oligonucleotides* , 1998, The Journal of Biological Chemistry.
[55] H. Pehamberger,et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice , 1998, Nature Medicine.
[56] G. Zon,et al. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. , 1994, Nucleic acids research.
[57] R. Kumar,et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. , 1994, The Journal of biological chemistry.
[58] P. Low,et al. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[59] A. Kabanov,et al. Polyion complex micelles with protein-modified corona for receptor-mediated delivery of oligonucleotides into cells. , 1999, Bioconjugate chemistry.
[60] H. D. Liggitt,et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery , 1997, Nature Biotechnology.
[61] L. Huang,et al. Plasmid DNA adsorbed to pH-sensitive liposomes efficiently transforms the target cells. , 1987, Biochemical and biophysical research communications.
[62] T. Abe,et al. Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A , 1999, Nature Biotechnology.
[63] F. Szoka,et al. Mechanism of oligonucleotide release from cationic liposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[64] J. C. Perales,et al. Receptor-mediated gene transfer into macrophages. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[65] M. Cotten,et al. Transferrin-polycation conjugates as carriers for DNA uptake into cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[66] M. Andreeff,et al. Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides , 1996, Journal of Molecular Medicine.
[67] S. Freier,et al. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. , 1991, The Journal of biological chemistry.
[68] A. Zimmer,et al. Use of liposomes, viral capsids, and nanoparticles as DNA carriers , 1991, Biotechnology and applied biochemistry.
[69] Y. Nagasaki,et al. Preparation and characterization of polymer micelles from poly(ethylene glycol)-poly(D,L-lactide) block copolymers as potential drug carrier. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[70] Doriano Fabbro,et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase , 1996, Nature Medicine.
[71] C. Wu,et al. Receptor-mediated gene delivery and expression in vivo. , 1988, The Journal of biological chemistry.
[72] F. Szoka,et al. How are nucleic acids released in cells from cationic lipid-nucleic acid complexes? , 1997 .
[73] W. Pardridge,et al. Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. , 1998, Journal of pharmaceutical sciences.
[74] J. C. Roberts,et al. Using starburst dendrimers as linker molecules to radiolabel antibodies. , 1990, Bioconjugate chemistry.
[75] L. Chaloin,et al. Conformations of primary amphipathic carrier peptides in membrane mimicking environments. , 1997, Biochemistry.
[76] H. Strey,et al. Improved DNA: liposome complexes for increased systemic delivery and gene expression , 1997, Nature Biotechnology.
[77] B. Calabretta,et al. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[78] L. Miraglia,et al. Characterization of a Potent and Specific Class of Antisense Oligonucleotide Inhibitor of Human Protein Kinase C-α Expression* , 1999, The Journal of Biological Chemistry.
[79] N M Dean,et al. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. , 1998, Nucleic acids research.
[80] P. Courtoy,et al. Intracellular routing and inhibitory activity of oligonucleopeptides containing a KDEL motif. , 1997, Molecular pharmacology.
[81] D. Fabbro,et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. , 1997, Journal of the National Cancer Institute.
[82] L. Chaloin,et al. A novel potent strategy for gene delivery using a single peptide vector as a carrier. , 1999, Nucleic acids research.
[83] M. Hope,et al. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review). , 1998, Molecular membrane biology.
[84] D. Papahadjopoulos,et al. Stabilization of cationic liposome‐plasmid DNA complexes by polyamines and poly(ethylene glycol)‐phospholipid conjugates for efficient in vivo gene delivery , 1997, FEBS letters.
[85] F. Szoka,et al. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. , 1993, Bioconjugate chemistry.
[86] M. Fresta,et al. Liposomal delivery of a 30-mer antisense oligodeoxynucleotide to inhibit proopiomelanocortin expression. , 1998, Journal of pharmaceutical sciences.
[87] D. Wielbo,et al. Antisense inhibition of angiotensinogen in hepatoma cell culture is enhanced by cationic liposome delivery. , 1997, Biochemical and biophysical research communications.
[88] J Barsoum,et al. Tat-mediated delivery of heterologous proteins into cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[89] P. Berg,et al. Rapid renaturation of complementary DNA strands mediated by cationic detergents: a role for high-probability binding domains in enhancing the kinetics of molecular assembly processes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[90] L. Chaloin,et al. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. , 1997, Nucleic acids research.
[91] M. Hashida,et al. Development of targeted delivery systems for nucleic acid drugs. , 1997, Journal of drug targeting.
[92] L. Chaloin,et al. Interactions of Primary Amphipathic Vector Peptides with Membranes. Conformational Consequences and Influence on Cellular Localization , 1998, The Journal of Membrane Biology.
[93] B. Davidson,et al. Complexes of Adenovirus with Polycationic Polymers and Cationic Lipids Increase the Efficiency of Gene Transfer in Vitro and in Vivo* , 1997, The Journal of Biological Chemistry.
[94] E. Nabel,et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[95] P. Low,et al. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. , 1994, The Journal of biological chemistry.
[96] Xiang Gao,et al. Cationic liposome-mediated gene transfer. , 1995, Gene therapy.
[97] R. Duff,et al. Intrabody tissue-specific delivery of antisense conjugates in animals: ligand-linker-antisense oligomer conjugates. , 2000, Methods in enzymology.
[98] M. Ariatti,et al. Evidence for targeted gene transfer by receptor-mediated endocytosis. Stable expression following insulin-directed entry of NEO into HepG2 cells. , 1990, Biochemical pharmacology.
[99] T. Ogihara,et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[100] D Needham,et al. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. , 1993, Cancer research.
[101] J. Frost,et al. Tissue distribution and metabolism of the [32P]-labeled oligodeoxynucleoside methylphosphonate-neoglycopeptide conjugate, [YEE(ah-GalNAc)3]-SMCC-AET-pUmpT7, in the mouse. , 1997, Antisense & nucleic acid drug development.
[102] C. Hélène,et al. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[103] B. Monia,et al. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation. , 1997, Molecular pharmacology.
[104] C. Hunt,et al. Antisense c-myc oligonucleotide cellular uptake and activity. , 1994, Antisense research and development.
[105] B. Froehler,et al. Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. , 1995, Biochemistry.
[106] A. Thierry,et al. Characterization of liposome-mediated gene delivery: expression, stability and pharmacokinetics of plasmid DNA , 1997, Gene Therapy.
[107] G. Zon,et al. Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. , 1993, Antisense research and development.
[108] R. Juliano,et al. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. , 1997, Journal of pharmaceutical sciences.
[109] R. Wagner. Gene inhibition using antisense oligodeoxynucleotides , 1994, Nature.
[110] K. Jayaraman,et al. Novel Polyaminolipids Enhance the Cellular Uptake of Oligonucleotides (*) , 1995, The Journal of Biological Chemistry.
[111] F. Szoka,et al. Association of a pH-sensitive peptide with membrane vesicles: role of amino acid sequence. , 1990, Biochemistry.
[112] J. Hughes,et al. In vitro transport and delivery of antisense oligonucleotides. , 2000, Methods in enzymology.
[113] R. Smith. The pathobiology of HIV infection. A review. , 1990, Archives of pathology & laboratory medicine.
[114] C. Stein,et al. Patterns of intracellular compartmentalization, trafficking and acidification of 5'-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. , 1994, Nucleic acids research.
[115] E. Kyle,et al. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. , 1996, Blood.
[116] P. Martiat,et al. Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides. , 1997, Blood.
[117] A. Frankel,et al. Increased cellular uptake of the human immunodeficiency virus-1 Tat protein after modification with biotin. , 1995, Analytical biochemistry.
[118] J. Baker,et al. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[119] T. V. van Berkel,et al. Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. , 1999, The Biochemical journal.
[120] P. Nielsen,et al. Cellular uptake of adamantyl conjugated peptide nucleic acids. , 1999, Bioconjugate chemistry.
[121] M. Hope,et al. Contact hypersensitivity: a simple model for the characterization of disease-site targeting by liposomes. , 1999, Biochimica et biophysica acta.
[122] C. Bennett,et al. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. , 1992, Molecular pharmacology.
[123] P. Davis,et al. Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor. , 1993, The Journal of clinical investigation.
[124] Y. Kaneda,et al. In vivo delivery of phosphorothioate oligonucleotides into murine retina. , 1998, Archives of ophthalmology.
[125] M. McCarthy. Modulating Gene Expression by Antisense Oligonucleotides to Understand Neural Functioning , 2012, Perspectives in Antisense Science.
[126] W. Pardridge,et al. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. , 1996, The Journal of pharmacology and experimental therapeutics.
[127] David E Reichert,et al. Self-Assembling Dendrimers , 1996, Science.
[128] D. Papahadjopoulos,et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.
[129] D. Scherman,et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[130] B. Lebleu,et al. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. , 1994, Nucleic acids research.
[131] J. Kuiper,et al. Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. , 1998, Molecular pharmacology.
[132] J. Nyce,et al. DNA antisense therapy for asthma in an animal model , 1997, Nature.
[133] C. Bennett,et al. Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity. , 2000, The Journal of pharmacology and experimental therapeutics.
[134] W. Stec,et al. Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogs of oligodeoxyribonucleotides , 1984 .
[135] J. Baker,et al. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. , 1996, Nucleic acids research.
[136] C. F. Bennett,et al. The Role of Antiapoptotic Bcl-2 Family Members in Endothelial Apoptosis Elucidated with Antisense Oligonucleotides* , 1999, The Journal of Biological Chemistry.
[137] M. Hashida,et al. Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine). , 1997, Biochemical pharmacology.
[138] R. Rando,et al. Inhibition of High Affinity Basic Fibroblast Growth Factor Binding by Oligonucleotides (*) , 1995, The Journal of Biological Chemistry.
[139] G. Storm,et al. Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. , 1992, Biochimica et biophysica acta.
[140] Y. Cheng,et al. Identification of two oligodeoxyribonucleotide binding proteins on plasma membranes of human cell lines. , 1996, Biochemical pharmacology.
[141] P. Couvreur,et al. Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. , 1999, Antisense & nucleic acid drug development.
[142] E. Lesnik,et al. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[143] L. Huang,et al. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. , 1995, Biochimica et biophysica acta.
[144] K. Moelling,et al. Integrin receptor-targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides , 1998, Journal of Molecular Medicine.
[145] R. Juliano,et al. Liposomes as a drug delivery system for antisense oligonucleotides. , 1992, Antisense research and development.
[146] Lois E. H. Smith,et al. Oligonucleotide-based inhibition of embryonic gene expression , 1999, Nature Biotechnology.
[147] D. Spiller,et al. Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. , 1995, Antisense research and development.
[148] A. Deisseroth,et al. Liposomal delivery of oligodeoxynucleotides. , 1996, Leukemia & lymphoma.
[149] T. Torgerson,et al. Inhibition of Nuclear Translocation of Transcription Factor NF-κB by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence (*) , 1995, The Journal of Biological Chemistry.
[150] M. Aoki,et al. In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method. , 1997, Biochemical and biophysical research communications.
[151] A. Prochiantz,et al. The third helix of the Antennapedia homeodomain translocates through biological membranes. , 1994, The Journal of biological chemistry.
[152] T. Hökfelt,et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo , 1998, Nature Biotechnology.
[153] P. Nielsen,et al. Peptide nucleic acids (PNA): synthesis, properties and potential applications. , 1996, Bioorganic & medicinal chemistry.
[154] S. Capaccioli,et al. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. , 1993, Biochemical and biophysical research communications.
[155] W. Stec,et al. Stereocontrolled Synthesis of Oligo(nucleoside phosphorothioate)s , 1994 .
[156] S. Morrison,et al. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. , 1999, Journal of immunology.
[157] L. Smith,et al. Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression. , 1994, Gene therapy.
[158] K. Koike,et al. In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. , 1996, Biochemical and biophysical research communications.
[159] G. Chaudhuri. Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages. Selective and efficient elimination of the parasite. , 1997, Biochemical pharmacology.
[160] G. Weissmann,et al. Phospholipid spherules (liposomes) as a model for biological membranes. , 1968, Journal of lipid research.
[161] G. Sczakiel,et al. Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset. , 1998, Blood.
[162] I. Gibson,et al. Interaction of oligodeoxynucleotides with mammalian cells. , 1996, Antisense & nucleic acid drug development.
[163] M. J. Martin,et al. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA , 1996, Antimicrobial agents and chemotherapy.
[164] R. Gurny,et al. Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization. , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[165] E. Richelson,et al. Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo , 1998, FEBS letters.
[166] E. Waelti,et al. Delivery to cancer cells of antisense L‐ myc oligonucleotides incorporated in fusogenic, cationic‐lipid‐reconstituted influenza‐virus envelopes (cationic virosomes) , 1998, International journal of cancer.
[167] M. Bally,et al. Generating and loading of liposomal systems for drug-delivery applications , 1989 .
[168] J. Summerton,et al. Morpholino antisense oligomers: design, preparation, and properties. , 1997, Antisense & nucleic acid drug development.
[169] A. Tomida,et al. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. , 1998, Blood.
[170] T Ochi,et al. A comparison of in vivo gene delivery methods for antisense therapy in ligament healing , 1998, Gene Therapy.
[171] S. Freier,et al. Kinetics of G-quartet-mediated tetramer formation. , 1996, Biochemistry.
[172] R. Ghirlando,et al. Mode of formation and structural features of DNA-cationic liposome complexes used for transfection. , 1993, Biochemistry.
[173] S. Agrawal,et al. In vivo studies with antisense oligonucleotides. , 1997, Trends in pharmacological sciences.
[174] L. Chaloin,et al. Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties. , 1998, Biochemical and biophysical research communications.
[175] L. Smith,et al. Efficient nuclear delivery of antisense oligodeoxynucleotides and selective inhibition of CETP expression by apo E peptide in a human CETP-stably transfected CHO cell line. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[176] F. Szoka,et al. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. , 1997, Biochemistry.
[177] G. Storm,et al. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. , 1993, Biochimica et biophysica acta.
[178] N. Dean,et al. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[179] V. Vlassov,et al. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[180] E. Wagner,et al. Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes. , 1994, Antiviral research.
[181] H. Farhood,et al. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. , 1995, Biochimica et biophysica acta.
[182] C. L. Douglas,et al. Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[183] D. Fitzpatrick,et al. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. , 1996, Cancer research.
[184] Joachim O. Rädler,et al. Structure of DNA-Cationic Liposome Complexes: DNA Intercalation in Multilamellar Membranes in Distinct Interhelical Packing Regimes , 1997, Science.
[185] M. Kamada,et al. Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits* , 1998, The Journal of Biological Chemistry.
[186] A. Prochiantz,et al. Cell Internalization of the Third Helix of the Antennapedia Homeodomain Is Receptor-independent* , 1996, The Journal of Biological Chemistry.
[187] P. Couvreur,et al. Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. , 1992, Biochemical and biophysical research communications.
[188] J. Northrop,et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[189] R. Wagner,et al. Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. , 1993, Nucleic acids research.
[190] M. Egholm,et al. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. , 1991, Science.
[191] M. Findeis,et al. Ligand-based carrier systems for delivery of DNA to hepatocytes. , 1994, Methods in enzymology.
[192] L. Huang,et al. Highly efficient DNA delivery mediated by pH-sensitive immunoliposomes. , 1989, Biochemistry.
[193] K. Fisher,et al. The transmembrane domain of diphtheria toxin improves molecular conjugate gene transfer. , 1997, The Biochemical journal.
[194] C. F. Bennett,et al. Progress in antisense oligonucleotide therapeutics. , 1996, Annual review of pharmacology and toxicology.
[195] H. Hutchinson,et al. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[196] S. Rotenberg,et al. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. , 1993, Biochemistry.
[197] N. Dean,et al. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. , 1998, The Journal of pharmacology and experimental therapeutics.
[198] W. Pardridge,et al. Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[199] J. Zweier,et al. The natural polyamine spermine functions directly as a free radical scavenger. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[200] A. Prochiantz,et al. Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro , 1995, The Journal of cell biology.
[201] R. Mayer,et al. The nuclear export signal-dependent localization of oligonucleopeptides enhances the inhibition of the protein expression from a gene transcribed in cytosol , 1999, Nucleic Acids Res..
[202] I. Wróbel,et al. Fusion of cationic liposomes with mammalian cells occurs after endocytosis. , 1995, Biochimica et biophysica acta.
[203] W. Stec,et al. Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. , 1995, Nucleic acids research.
[204] M. Watabe,et al. Binding of oligonucleotides to cell membranes at acidic pH. , 1991, Biochemical and biophysical research communications.
[205] E. Wickstrom,et al. Down-regulation of c-MYC antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. , 1992, Cancer research.
[206] R. Kole,et al. Novel cationic amphiphiles as delivery agents for antisense oligonucleotides. , 1999, Nucleic acids research.
[207] Wei Xin,et al. Treatment of duck hepatitis B virus by antisense poly-2'-O-(2,4-dinitrophenyl)-oligoribonucleotides. , 1998, Antisense & nucleic acid drug development.
[208] V V Demidov,et al. Stability of peptide nucleic acids in human serum and cellular extracts. , 1994, Biochemical pharmacology.
[209] L. Huang,et al. DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. , 1994, Biochimica et biophysica acta.
[210] G. Citro,et al. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. , 1997, Anticancer research.
[211] A. Tari,et al. Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. , 1999, The Journal of pharmacology and experimental therapeutics.
[212] S. Crooke,et al. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. , 1995, The Journal of pharmacology and experimental therapeutics.
[213] S. Akhtar. Delivery strategies for antisense oligonucleotide therapeutics , 1995 .
[214] B. Calabretta,et al. A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. , 1988, Science.
[215] M. Cotten,et al. Transferrin-polycation-DNA complexes: the effect of polycations on the structure of the complex and DNA delivery to cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[216] M. Yarmush,et al. Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[217] A. Zimmer,et al. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. , 1999, Methods.
[218] Y. Cheng,et al. Antisense oligonucleotides as therapeutic agents--is the bullet really magical? , 1993, Science.
[219] Leaf Huang,et al. Folate-targeted, Anionic Liposome-entrapped Polylysine-condensed DNA for Tumor Cell-specific Gene Transfer (*) , 1996, The Journal of Biological Chemistry.
[220] N. Goldstein,et al. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[221] I. D'Agnano,et al. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[222] Pierre Vidal,et al. Nouvelle stratégie pour vectorisation d'ARN dans des cellules de mammifères. Utilisation d'un vecteur peptidique , 1997 .
[223] C. Stein,et al. Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix (*) , 1995, The Journal of Biological Chemistry.
[224] R. Crooke,et al. Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture. , 1998, Journal of drug targeting.
[225] B. Peng,et al. Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles conjugated to ferric protoporphyrin IX (heme). , 1997, Antisense & nucleic acid drug development.
[226] J. Pow-Sang,et al. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. , 1993, Cancer research.
[227] P. Low,et al. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.